If you believe you can contribute to the Precision Cancer Consortium and our vision, please get in touch
Membership enquiry
An organization may be eligible for Precision Cancer Consortium (PCC) membership if the following criteria are met:
- is a pharmaceutical or biotechnology organisation
AND
- engages in or supports the discovery, development, research, or testing of interventions and diagnostics related to precision oncology.
Why join the PCC
The PCC is dedicated to a future where every person with cancer—regardless of who they are or where they live—can benefit from precision oncology. Through global collaboration, we work to make biomarker-informed, data-driven patient identification and personalized care standard practice.
By joining the PCC, you can:
Shape the future of biomarker testing in a way that you cannot do on your own
Challenges that are ecosystem-related cannot be solved by one stakeholder of the healthcare system alone. The PCC has an impartiality and collective credibility beyond a single pharmaceutical company. This allows the PCC to accomplish more than any individual company.
Demonstrate your commitment to patients and the wider medical community
The PCC is a non-profit organization, and our projects are never product-related or commercially driven. They are chosen on the basis of improving biomarker testing for all patients.
Maximize resource utilization and reach
Collaborate with fellow subject matter experts to share resources and leverage existing materials for new audiences to extend reach.
PCC areas of interest
The PCC’s core areas of interest include the following:
- Access to comprehensive genomic profiling (CGP) follow-on: policy shaping in Japan
- Liquid biopsy (LBx) follow-on: minimal residual disease (MRD) and monitoring in the USA
- Digital and computational pathology and artificial intelligence (AI)
- Biomarker testing standardization
PCC-251 | January 2026
PCC Members
The PCC is a group of four pharmaceutical companies with a shared vision, coming together to address challenges regarding access, awareness, and research & development of comprehensive genomic testing for cancer patients globally.
The PCC is a non-profit organization.